Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
SpyGlass Pharma has acquired Advanced Vision Science (AVS), the supplier of intraocular lenses (IOLs) for its investigational bimatoprost drug pad-IOL (BIM-IOL) system, for $13 million in cash. The deal secures SpyGlass's long-term IOL supply as it advances two phase 3 trials of the BIM-IOL system. It also opens the door to a broader portfolio of premium lenses, including toric and extended depth of focus options.
SpyGlass Pharma has acquired Advanced Vision Science (AVS) — formerly a subsidiary of Santen Pharmaceutical — for $13 million in cash, gaining full control of a key manufacturing partner as it advances its bimatoprost drug pad-IOL (BIM-IOL) system through two ongoing phase 3 trials. The BIM-IOL system is designed to deliver glaucoma therapy directly via an IOL-mounted bimatoprost implant, targeting patients with both cataracts and glaucoma or ocular hypertension.
The move gives SpyGlass ownership of proven IOL manufacturing capabilities while preserving existing commercial relationships — AVS will continue supplying Santen with select IOLs for the Japanese market and licensing lens material to Bausch + Lomb for its enVista IOL line.
CEO Patrick Mooney noted that the acquisition positions SpyGlass to expand beyond its monofocal IOL into premium options like toric and extended depth of focus lenses, broadening the potential patient population that could benefit from its drug delivery platform.
By the Numbers:
Why it matters: Securing its own IOL supply chain reduces a critical dependency for SpyGlass as it approaches pivotal trial readouts, and signals ambitions to compete in the premium IOL market — a move that could meaningfully expand its commercial opportunity in glaucoma and cataract care.
